Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep 14;12(1):99.
doi: 10.1186/s13045-019-0788-4.

TCR-like antibodies in cancer immunotherapy

Affiliations
Review

TCR-like antibodies in cancer immunotherapy

Qinghua He et al. J Hematol Oncol. .

Abstract

Cancer immunotherapy has been regarded as the most significant scientific breakthrough of 2013, and antibody therapy is at the core of this breakthrough. Despite significant success achieved in recent years, it is still difficult to target intracellular antigens of tumor cells with traditional antibodies, and novel therapeutic strategies are needed. T cell receptor (TCR)-like antibodies comprise a novel family of antibodies that can recognize peptide/MHC complexes on tumor cell surfaces. TCR-like antibodies can execute specific and significant anti-tumor immunity through several distinct molecular mechanisms, and the success of this type of antibody therapy in melanoma, leukemia, and breast, colon, and prostate tumor models has excited researchers in the immunotherapy field. Here, we summarize the generation strategy, function, and molecular mechanisms of TCR-like antibodies described in publications, focusing on the most significant discoveries.

Keywords: Antibody; Immunotherapy; T cell receptor; TCR-like antibody; Tumor antigen.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Schematics of T cell receptor (TCR) and TCR-like receptor. Both TCR and TCR-like antibodies recognize the peptide/MHC complex on the surface of tumor cells
Fig. 2
Fig. 2
The molecular mechanisms of TCR-like antibodies against tumor cells. TCR-like antibodies mediate their anti-tumor effects through multiple mechanisms. (a) Conjugation with fluorescent reagents to detect the expression of the peptide/MHC complex on the surface of tumor cells. (b) Antibody-dependent cell-mediated cytotoxicity (ADCC) with NK cells. (c) Complement-dependent cytotoxicity (CDC) with complements. (d) Antibody-dependent cellular phagocytosis (ADCP) with microphages. (e) Direct induction of tumor cell apoptosis. (f) Conjugation with drugs or toxins. (g) Conjugation as a bi-specific T cell engager (BiTE). (h) CAR-T strategy. TCR-like: T cell receptor-like; MHC: major histocompatibility complex; MAC: membrane attack complex; FcγR: Fc gamma receptor; FcγR IIα: Fc gamma receptor II alpha

Similar articles

Cited by

References

    1. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science. 2013;342(6165):1432–1433. doi: 10.1126/science.342.6165.1432. - DOI - PubMed
    1. Almagro JC, et al. Progress and challenges in the design and clinical development of antibodies for cancer therapy. Front Immunol. 2017;8:1751. doi: 10.3389/fimmu.2017.01751. - DOI - PMC - PubMed
    1. Strohl WR. Current progress in innovative engineered antibodies. Protein Cell. 2018;9(1):86–120. doi: 10.1007/s13238-017-0457-8. - DOI - PMC - PubMed
    1. Rexer BN, Arteaga CL. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit Rev Oncog. 2012;17(1):1–16. doi: 10.1615/CritRevOncog.v17.i1.20. - DOI - PMC - PubMed
    1. Klein C, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs. 2013;5(1):22–33. doi: 10.4161/mabs.22771. - DOI - PMC - PubMed

Publication types